Table 2. PFS and OS according to baseline characteristics.
| Variables | Number | Median PFS (months) | p valuea | Median OS (months) | p valuea |
|---|---|---|---|---|---|
| All | 226 | 11.9 (10.4–13.3) | NA | 26.9 (21.2–32.5) | NA |
| Age | |||||
| ≥70 y/o | 87 | 12.1 (8.8–15.4) | .261 | 23.4 (15.5–31.3) | .24 |
| <70 y/o | 139 | 11.4 (9.9–12.9) | 28.4 (20.3–36.6) | ||
| Gender | |||||
| Female | 147 | 11.9 (9.7–14.1) | .211 | 28.4 (17.5–39.3) | .315 |
| Male | 79 | 11.6 (10.6–12.6) | 23.4 (17.6–29.2) | ||
| Smoking history | |||||
| <20 pack‐years | 190 | 12.1 (10.4–13.8) | .362 | 32.4 (23.7–41.1) | .003 |
| ≥20 pack‐years | 36 | 10.6 (8.7–12.5) | 18.5 (9.5–27.6) | ||
| Performance status | |||||
| ECOG <2 | 200 | 12.1 (10.3–13.9) | .001 | 29.0 (21.9–36.2) | <.001 |
| ECOG ≥2 | 26 | 9.6 (8.4–10.7) | 14.0 (8.0–20.0) | ||
| Stage | |||||
| IIIB | 5 | 9.6 (9.5–9.6) | .285 | 39.3 (7.9–70.6) | .704 |
| IV | 221 | 11.9 (10.4–13.3) | 25.7 (19.9–31.6) | ||
| EGFR mutation status | |||||
| Exon 19 deletion | 104 | 11.9 (10.1–13.7) | <.001 | 32.7 (16.8–48.6) | .136 |
| L858R | 111 | 11.9 (9.7–14.2) | 24.7 (20.8–28.5) | ||
| Uncommon mutation | 7 | 8.8 (4.3–13.4) | 38.4 (0–78.5) | ||
| Complex | 4 | 2.7 (0–7.8) | 12.9 (0.4–25.4) | ||
| HBV status | |||||
| HBV (+) | 36 | 10.3 (5.7–14.8) | .227 | 25.5 (NA) | .656 |
| HBV (−) | 145 | 11.8 (10.2–13.4) | 23.8 (19.9–27.8) | ||
| Unknown HBV status | 45 | 11.9 (9.7–14.1) | 32.7 (24.8–40.5) | ||
| HCV status | |||||
| HCV (+) | 12 | 5.6 (4.1–7.1) | .39 | 14.1 (10.3–17.9) | .004 |
| HCV (−) | 171 | 11.9 (10.2–13.5) | 28.4 (17.9–39.0) | ||
| Unknown HCV status | 43 | 11.9 (9.8–14.0) | 25.5 (17.7–33.3) | ||
| Disease status | |||||
| Post‐op recurrence | 18 | 17.3 (1.6–33.0) | .12 | NR | .018 |
| Advanced NSCLC | 208 | 11.4 (10.0–12.8) | 24.7 (21.0–28.3) | ||
| Pathology | |||||
| Adenocarcinoma | 224 | 11.9 (10.4–13.3) | NA | 26.9 (20.8–32.9) | NA |
| Adenosquamous cell carcinoma | 1 | 3.3 | 33.4 | ||
| NOS | 1 | 6.1 | 19.1 | ||
| M1a | 75 | 14.9 (11.0–18.3) | .001b | 33.2 (19.3–47.1) | .08b |
| Brain metastasis | 63 | 9.9 (8.3–11.6) | .02c | 20.7 (16.4–25.0) | .042c |
| Bone metastasis | 111 | 10.3 (8.8–11.9) | .001d | 23.6 (19.9–27.2) | .1d |
| Liver metastasis | 24 | 8.9 (5.9–11.8) | <.001e | 13.2 (5.9–20.5) | <.001e |
a
Log‐rank test.
b
Versus extra‐pulmonary metastasis.
c
Versus without brain metastasis.
d
Versus without bone metastasis.
e
Versus without liver metastasis.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HBV, hepatitis B virus; HCV, hepatitis C virus; NA, not applicable; NOS, not otherwise specified; NR, not reached; OS, overall survival; PFS, progression‐free survival.